Incyte (NASDAQ:INCY – Get Rating) was upgraded by investment analysts at TheStreet from a “c+” rating to a “b” rating in a research note issued to investors on Monday, TheStreetRatingsTable reports. Several other equities analysts have also recently commented on the stock. Royal Bank of Canada raised shares of Incyte from a “sector perform” rating […]
Kodiak Sciences (NASDAQ:KOD – Get Rating)‘s stock had its “buy” rating reiterated by equities research analysts at Chardan Capital in a note issued to investors on Monday, Zacks.com reports. Other equities research analysts have also recently issued research reports about the company. Barclays dropped their price objective on Kodiak Sciences from $81.00 to $50.00 and […]
Kodiak Sciences (NASDAQ:KOD – Get Rating) had its price target cut by Morgan Stanley from $17.00 to $12.00 in a report issued on Tuesday, MarketBeat reports. They currently have an equal weight rating on the stock. Several other analysts have also recently issued reports on KOD. JPMorgan Chase & Co. cut Kodiak Sciences from an […]
Analysts expect that Incyte Co. (NASDAQ:INCY – Get Rating) will announce $0.50 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Incyte’s earnings, with estimates ranging from $0.39 to $0.61. Incyte posted earnings per share of $0.67 in the same quarter last year, which would […]
Allspring Global Investments Holdings LLC acquired a new position in Incyte Co. (NASDAQ:INCY – Get Rating) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 109,461 shares of the biopharmaceutical company’s stock, valued at approximately $8,034,000. Several other large investors have also modified […]